Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development

Stock Information for Predictive Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Predictive Oncology Inc.

Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Predictive Oncology to Participate in Upcoming Investor Conferences
Predictive Oncology to Participate in Upcoming San Francisco Conferences
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.